⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 29, 2021Journal of Clinical OncologyOpen Access

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

View Full Paper

Ask AI

Bookmark

Share

Abstract

Poziotinib demonstrates antitumor activity in previously treated patients with HER2 exon 20 insertion NSCLC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Le et al. (2021) studied this question.

synapsesocial.com/papers/69d73a94b54ccf0cfef30947 https://doi.org/10.1200/jco.21.01323

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

1The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyLate-Phase Clinical Trial · 1993 · 16,006 citations
2Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro studyClinical Trial · 2018 · 68 citations
3Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung AdenocarcinomaOriginal Research · 2019 · 62 citations
4HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to PyrotinibCase Report · 2020 · 11 citations